Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH TSX:AUP) ( Aurinia or the Company ) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
Merck: FDA Grants Priority Review To SBLA For Keytruda Plus Chemotherapy
KENILWORTH (NJ) (dpa-AFX) - Merck & Co. Inc. (MRK) said Thursday that the U.S. Food and Drug Administration has granted priority review for a new supplemental Biologics License Application or sBLA for KEYTRUDA in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ).
This sBLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial. In the trial, KEYTRUDA plus chemotherapy demonstrated significant improvements in the primary endpoints of overall survival (OS) and progression-free survival (PFS), versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. KEYTRUDA is Merck s anti-PD-1 therapy.
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – – Agreement includes royalties of up to 20 percent on net sales payable to Aurinia – Aurinia Pharmaceuticals Inc. today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral … – Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments –
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
Biohaven s Rimegepant For Preventive Treatment Of Migraine Published In The Lancet marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.